The biotech landscape is poised for potential shifts as an associate of Jeffrey Epstein attempts to re-enter the sector. This move raises questions about regulatory scrutiny and public perception.
In parallel, the departure of Prasad from the FDA could impact ongoing and future biotech initiatives. His exit may signal changes in regulatory approaches that could affect industry dynamics.
Stakeholders should monitor these developments closely, as they may influence investment strategies and operational frameworks within the biotech industry.
Updates
Update at 13:54 UTC on 2026-03-13
STAT reported Epstein's pal returns to biotech, Prasad's FDA exit part deux, and more news from The Readout.
Sources: STAT